ZTS · Zoetis Inc.
$73.79
-2.05 (-2.70%)
At close · Aug 14
Market Cap
$30.49B
Shares
413.22M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$73.79
Open$75.52
Day$73.61–76.37
52W close$71.86–156.76
Avg vol 30d6.6M
Short int21.4M · 5.2% float · 3.9d
Short vol29%
Last earningsAug 6, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 6
Up next
Next earnings call
Nov 2, 2026
Est · unconfirmed
· in 11 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 6, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Bearish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−31%
below
Price vs 50-day avg
−3%
below
RSI (14)
45
neutral
MACD trend
Negative
52-week position
2%
near low
Momentum
relative strength
1-month return
−4%
trailing
6-month return
−41%
trailing
YTD return
−41%
this year
Relative strength
−55%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $76 › 200d $107 — 200d above 50d
Institutional flow
Distributing
-14% holders QoQ · +167 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
5.17% of float · ▲ +13.6% MoM · 3.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
1,395 holders — near 3-yr low, contrarian setup
Squeeze score
62
elevated · 0–100
Fundamentals
Revenue growth
+2%
Y/Y
EPS growth
+10%
Y/Y
Free cash flow
$2.3B
Valuation
P/E 12.1
below peers
Buyback
$1.3B
remaining
Balance sheet
$7.1B
net debt
Quant / Vol
risk profile
Volatility
37%
annualized · 1-yr
Max drawdown
−54%
past year
ATR
4.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 6, 2026
Revenue
· Full Year 2026
$9.12B – $9.32B
Adjusted Diluted EPS
· Full Year 2026
Non-GAAP
$6.15 – $6.25
Prior guidance
period ended
· from the 8-K filed Nov 4, 2025
Revenue
· full year 2025
$9.4B – $9.48B
Reported net income
· full year 2025
$2.63B – $2.67B
Adjusted net income
· full year 2025
$2.8B – $2.84B
Reported diluted EPS
· full year 2025
$5.90 – $6.00
Adjusted diluted EPS
· full year 2025
$6.30 – $6.40
Organic operational growth
· Full Year 2025
5.5% – 6.5%
Adjusted cost of sales as a percentage of revenue
· Full Year 2025
28.3%
Effective tax rate on adjusted income
· Full Year 2025
20.5%
Guided vs delivered
· last 4 settled
Revenue
full year 2025
guided $9.4B – $9.48B
$9.47B
In line
Reported diluted EPS
full year 2025
guided $5.90 – $6.00
$6.02
Beat +1.2%
Revenue
full year of 2024
guided $9.08B – $9.23B
$9.26B
Beat +1.2%
Reported diluted EPS
2024
guided $5.34 – $5.44
$5.47
Beat +1.5%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−31%
Bearish
Price vs 50-day avg
−3%
Neutral
RSI (14)
45
Neutral
MACD trend
Negative
Bearish
52-week position
2%
Bearish
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $76 › 200d $107 — 200d above 50d
Institutional flow
Distributing
-14% holders QoQ · +167 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
5.17% of float · ▲ +13.6% MoM · 3.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
1,395 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $72
Now $74 · 2%
Range high $157
vs 200-day avg -31%
vs 50-day avg -3%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ZTS
this stock
Zoetis Inc.
|
$30.49B | -41.4% | +2.3% | 12.1 | 5.2% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$64.91B | — | — | — | 0.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$56.30B | +13.1% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$49.49B | +2.4% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$42.85B | +17.8% | +4.3% | 60.3 | 2.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ZTS | +1.6% | -3.6% | -41.3% | -4.5% | -41.4% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | +1.2% | -8.1% | -55.1% | -8.5% | -55.2% |
Capital returns
Latest dividend
$0.53
/ share · ex Jul 20, 2026
Paid (TTM)
$2.09
/ share · 4 payouts
Dividend yield (TTM, derived)
2.83%
Buyback program
· as of Jun 30, 2026
Authorized
$6.00B
Spent (derived)
$4.70B
Remaining
$1.30B
Spent
Remaining
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
Key facts
CIK
1555280
CUSIP
98978V103
13F (30d)
1277 filings
1227 filers
Visit website
Investor relations